Richard D Lopez, MD

Associate Professor of Medicine
Campus mail Box 3961 Med Ctr, Durham, NC 27710
Phone (919) 668-1000
Email address richard.lopez@duke.edu

Education and Training

  • Resident, Medicine, Stanford University School of Medicine, 1990 - 1991
  • Intern, Medicine, Stanford University School of Medicine, 1989 - 1990
  • M.D., Stanford University, 1989

Publications

Suarez-Cuervo, C., N. L. Bryant, R. D. Lopez, G. Y. Gillespie, and L. S. Lamb. “Ex vivo activation and expansion of γδ T cells for immunotherapy of glioblastoma..” J Clin Oncol 24, no. 18_suppl (June 20, 2006).

PMID
27954891
Scholars@Duke

Gehrs, B. C., and R. D. Lopez. “Ex vivo expansion of gamma delta-T lymphocytes from melanoma patients and healthy control donors.” In Transfusion, 45:8A-8A. BLACKWELL PUBLISHING, 2005.

Scholars@Duke

Guo, Ben L., Zhiyong Liu, Wayne A. Aldrich, and Richard D. Lopez. “Innate anti-breast cancer immunity of apoptosis-resistant human gammadelta-T cells..” Breast Cancer Res Treat 93, no. 2 (September 2005): 169–75. https://doi.org/10.1007/s10549-005-4792-8.

PMID
16187237
Full Text

Liu, Zhiyong, Ben L. Guo, Bradley C. Gehrs, Li Nan, and Richard D. Lopez. “Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro..” J Urol 173, no. 5 (May 2005): 1552–56. https://doi.org/10.1097/01.ju.0000154355.45816.0b.

PMID
15821484
Full Text

Guo, Ben L., Klaus A. Hollmig, and Richard D. Lopez. “Down-regulation of IL-2 receptor alpha (CD25) characterizes human gammadelta-T cells rendered resistant to apoptosis after CD2 engagement in the presence of IL-12..” Cancer Immunol Immunother 50, no. 11 (January 2002): 625–37. https://doi.org/10.1007/s00262-001-0244-4.

PMID
11807626
Full Text

Vaughan, W. P., R. O. Katz, D. E. Salzman, A. B. Tilden, R. D. Lopez, A. Garcia, O. Pena, M. Shackelford, and M. H. Carabasi. “MRD allo transplantation using a large volume leukopheresis product mobilized with G-CSF and Decadron, pharmacokinetics directed modest dose intravenous busulfan plus fludarabine conditioning, and long MTX/CSA results in sustained engraftment, low 30 day mortality, and low incidence of severe GVHD..” Blood 98, no. 11 (November 16, 2001): 200A-200A.

Scholars@Duke

Lopez, R. D., E. K. Waller, P. H. Lu, and R. S. Negrin. “CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells..” Cancer Immunol Immunother 49, no. 12 (February 2001): 629–40.

PMID
11258789
Scholars@Duke

Lopez, R. D., E. K. Waller, P. H. Lu, and R. S. Negrin. “CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells.” Cancer Immunology, Immunotherapy 49, no. 11 (December 1, 2000): 629–40.

Scholars@Duke

Pages